Navigation Links
CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
Date:6/1/2008

- Data presented at the 2008 ASCO Annual Meeting -

- Conference call to be hosted Wednesday, June 4 at 9:00 a.m. EDT to

discuss results -

BRANFORD, Conn., June 1 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN) today presented encouraging results from the ongoing Phase I/II study of CR011-vcMMAE for the treatment of unresectable Stage III or Stage IV melanoma. The results were presented by Dr. Patrick Hwu, Co-Principal Investigator, and Professor, Chairman, Dept. of Melanoma Medical Oncology at The University of Texas, M.D. Anderson Cancer Center.

"In this heavily pretreated group of patients with primarily Stage IV disease, the observation of dose-dependent objective responses, tumor shrinkage, and encouraging early progression-free rate at 12 weeks at doses in the anticipated active range, leads us to believe that CR011-vcMMAE could be a potentially useful treatment for patients with advanced melanoma," commented Dr. Timothy Shannon, President and Chief Executive Officer of CuraGen Corporation. "Based on these promising results in melanoma we have expanded the CR011-vcMMAE development program to include a Phase II trial in metastatic breast cancer, and are also exploring additional doses and schedules to further optimize the activity of this antibody-drug conjugate."

As of April 4, 2008, forty patients were treated in this first-in-man Phase I/II study including a total of 32 patients in the Phase I dose-escalation portion of the trial that aimed to identify the safety and maximum tolerated dose (MTD) of CR011-vcMMAE and 8 patients in the ongoing Phase II portion of the study. During Phase I, doses of CR011-vcMMAE between 0.03 mg/kg to 2.63 mg/kg were evaluat
'/>"/>

SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014  VigeneTech, Inc, in collaboration with ... Data Analysis Software, an OEM software solution for ... develops and offers varieties of bead-based multi-analyte immunoassay ... support of VigeneTech,s data analysis software, FCS data ... easily reported LEGENDplex™ software is ...
(Date:7/28/2014)... Research and Markets  has announced the addition of the ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... pain in the human body,s joints such as wrists, fingers, ... the tissues that surround the joints and in other organs. ... usually just mild pain around the joints coupled with stiffness ...
(Date:7/28/2014)... July 28, 2014  Syneron Medical Ltd. (NASDAQ: ... announced today that its new PicoWay® device has received ... and colors and pigmented lesions on any skin type. ... with 532nm and 1064nm wavelengths, which utilizes Syneron,s proprietary ... pulses which are trillionths of a second, known as ...
Breaking Medicine Technology:VigeneTech Releases New Powerful Software for Flow Cytometry Data Analysis 2Global Rheumatoid Arthritis Drugs Market 2014-2018 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4
... Thomson CompuMark , the global leader in trademark ... Reuters, today announced the launch of Global Pharmaceutical ... intelligence in a single online report. Avoiding ... to prescription errors, is a critically important public health ...
... Span-America Medical Systems, Inc. (NASDAQ:  SPAN) will provide ... call on Friday, February 3, 2012, covering results for ... after the regular close of trading the preceding day. ... will be available online at www.spanamerica.com under ...
Cached Medicine Technology:Thomson CompuMark Reduces Drug Approval Delays by Identifying Conflicting Trademarks in International Markets 2Thomson CompuMark Reduces Drug Approval Delays by Identifying Conflicting Trademarks in International Markets 3
(Date:7/28/2014)... 29, 2014 NAPW honors ... County Hospital Center, as a 2014 Professional Woman of ... distinction for leadership in community health. As the largest, ... virtually every industry and profession, the National Association of ... with over 600,000 members and nearly 300 Local Chapters. ...
(Date:7/28/2014)... July 29, 2014 The ... Situ Hybridization, Digital pathology & Workflow, Special ... Prostate Cancer, Non Small Cell Lung Cancer ... (Hospitals, Pharmaceutical companies, Research Laboratories, Contract Research ... Americas, Europe, BRIC, Japan & RoW) - ...
(Date:7/28/2014)... Scottsdale, Ariz (PRWEB) July 28, 2014 ... closed on a new camp property in Cornville, ... provides seriously ill children with the opportunity to ... the campers and families. The organization offers a ... ages 6-15 with chronic and life threatening illnesses ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 An estimated ... year from metastatic breast and prostate cancers – an ... cancer has spread to other parts of the body, ... researchers at Drexel University College of Medicine ... identified that inhibits metastatic progression by blocking tumor cells ...
(Date:7/28/2014)... version of a surgical procedure to treat severe chronic ... 90 percent of the time in patients treated at ... Division of Plastic and Reconstructive Surgery report that more ... procedure all of whom had headaches associated with ... a year later. The team,s paper has received ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Announces Pamela A. Schulters, Head Nurse at Kings County Hospital Center, a 2014 Professional Woman of the Year 2Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 2Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 3Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 4Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 5Health News:Camp Soaring Eagle Announces New Camp Site 2Health News:Camp Soaring Eagle Announces New Camp Site 3Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 2Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 3Health News:Non-endoscopic migraine surgery provides significant symptom relief 2
... new and novel computer modeling platform developed through intensive, ... and cities to be more prepared for catastrophic public ... American Medical Association,s Disaster Medicine and Public Health ... to Multihazard Modeling and Simulation," is based on the ...
... Telemedicine, Mammography and Health Screenings on Wheels Expand Access ... June 11 Kaiser Permanente, one of America,s leading ... a new generation of mobile health. A first-of-its-kind, 500-sq-foot, ... home island of Hawaii, known to many as the ...
... off brain cell damage, lab study finds , THURSDAY, June ... may start with one protein that somehow goes astray and ... say. , Mad cow disease is considered a prion disease ... prion protein, or PrP, which normally is found on the ...
... is pleased to offer its stock alerts service to ... move and in the news can receive FREE Alerts by visiting ... , Today,s focused alerts include: Hemispherx Biopharma, Inc. (Amex: ... Cell Therapeutics, Inc. (Nasdaq: CTIC ), Cancer Therapeutics Inc. ...
... June 11 National figures, stars from the world of sports ... gathered today in Anaheim, California to celebrate 20 years of Drug ... reach of every American in need at the National Association of ... , Speaking in front of a crowd representing every U.S. state ...
... most common cancers in China. Although the association between ... studied, the relation between smoking, alcohol drinking, family history ... cancer still remains uncertain. So it is important to ... of sporadic colorectal cancer. A research team led ...
Cached Medicine News:Health News:A new computer modeling program can help hospitals prepare for the worst 2Health News:Kaiser Permanente Unveils the Nation's Most Wired Mobile Health Vehicle 2Health News:Kaiser Permanente Unveils the Nation's Most Wired Mobile Health Vehicle 3Health News:Protein Branded As Culprit in Mad Cow Disease 2Health News:GlobalEquityReport.com Issues Cancer Stocks On The Move Today: HEB, GNBT, CTIC, CTHP, DNDN 2Health News:U.S. Drug Czar Addresses 2,500 Drug Court Professionals, Voices Strong Support for Expanding Drug Courts Throughout the Nation 2Health News:U.S. Drug Czar Addresses 2,500 Drug Court Professionals, Voices Strong Support for Expanding Drug Courts Throughout the Nation 3
...
... FLEXILOG antimony pH catheters are designed for patient ... ,All catheters are number marked at 5cm intervals ... than sixteen individual models are available spanning most ... or multi-use models with one or two sensors., ...
... The Standard VersaFlex™ disposable pH ... nurses, and clinics worldwide for evaluating ... catheters for 24-hour esophageal pH monitoring. ... the smallest diameter esophageal catheter on ...
FLEXILOG accessory....
Medicine Products: